| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 15.2MM | +67% |
| Operating Income | -47.5MM | -6% |
| Operating Expenses | 62.6MM | +5% |
| Net Income | -41.4MM | -7% |
| R&D | 47.7MM | +3% |
| G&A | 14.9MM | +12% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
We're definitely into long term investing, but some companies are simply bad investments over any time frame. We really...
Alector, Inc. ( NASDAQ:ALEC ) defied analyst predictions to release its full-year results, which were ahead of market...
One thing we could say about the analysts on Alector, Inc. ( NASDAQ:ALEC ) - they aren't optimistic, having just made a...
Q4 2023 Alector Inc Earnings Call
Alector, Inc. (NASDAQ:ALEC) Q4 2023 Earnings Call Transcript February 27, 2024 Alector, Inc. beats earnings expectations. Reported EPS is $-0.49, expectations were $-0.8. Alector, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for standing […]
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences: TD Cowen 44th Annual Health Care Conference (Boston, Massachusetts) Tuesday, March 5, 2024, at 10:30 a.m. ET, panel Leerink Partners Global Biopharma Conference (Miami, Florida) Tuesday, March 12, 2024, at 10:40 a.m. ET, corporate presentatio
Key Financial Highlights and Clinical Advancements
Data from INVOKE-2, evaluating the most advanced TREM2 candidate in clinical development for early Alzheimer’s disease (AD), expected in Q4 2024; trial enrollment completed in Q3 2023 First participant in the global PROGRESS-AD Phase 2 clinical trial of AL101 in early AD dosed in Q1 2024 Latozinemab granted FDA’s Breakthrough Therapy Designation for frontotemporal dementia due to a mutation in the progranulin gene (FTD-GRN) Achieved target enrollment in pivotal INFRONT-3 latozinemab Phase 3 tria
Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PTSOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it will host a conference call and webcast on Tuesday, February 27, 2024, at 4:30 p.m. ET to discuss results for the fourth quarter ended December 31, 2023, and provide a full-year business update. A press release detailing fourth quarter results w
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.